Hyderabad, India, and Copenhagen, Denmark; April 19, 2024: Aurigene Pharmaceutical Services Ltd. (Aurigene), a global contract research, development, and manufacturing services organization (CRDMO), and Vipergen ApS, a niche small-molecule drug discovery service provider specialized in DEL technologies, entered into a strategic partnership.

印度海得拉巴和丹麦哥本哈根；2024年4月19日：全球合同研究、开发和制造服务组织（CRDMO）Aurigene Pharmaceutical Services Ltd.（Aurigene）与专门从事DEL技术的利基小分子药物发现服务提供商Vipergen ApS达成战略合作伙伴关系。

The collaboration aims to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service. The two companies will also co-develop new DELs with an emphasis on novel chemical diversity and drug-likeness to further strengthen their service offering..

该合作旨在将DEL筛选技术作为独立服务或综合药物发现服务共同营销并提供给全球客户。两家公司还将共同开发新的DEL，重点是新型化学多样性和药物相似性，以进一步加强其服务。。

Vipergen’s high-fidelity DEL screening technologies would be a strategic addition to Aurigene’s existing small molecule discovery capabilities, from compound resynthesis to candidate nomination. With the addition of hit screening capabilities, Aurigene would be able to enhance its Integrated Drug Discovery (IDD) service offering to its global customers..

Vipergen的高保真DEL筛选技术将是Aurigene现有小分子发现能力的战略性补充，从化合物再合成到候选人提名。通过增加命中筛选功能，Aurigene将能够增强其向全球客户提供的综合药物发现（IDD）服务。。

'The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer-centric approach. The recent launch of Aurigene.AI for small molecules and DEL partnership with Vipergen aim to reduce the hit finding timelines. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us.', said Akhil Ravi, CEO, Aurigene..

“与Vipergen的合作关系强调了我们致力于加速创新和以客户为中心的方法。最近推出的Aurigene。AI for small molecules和DEL与Vipergen的合作旨在缩短寻找命中的时间表。奥里根首席执行官Akhil Ravi说：“Vipergen的业绩证明，与大型制药和生物技术公司建立了90多个合作伙伴关系，以及他们简化的热门搜索平台，使Vipergen成为我们理想的战略合作伙伴。”。。

'We are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.', said Nils Jakob Vest Hansen, PhD, CEO, Vipergen..

“我们很高兴与专注于客户服务的全球CRDMO Aurigene合作。Aurigene的药物发现能力和全球影响力与Vipergen完美匹配。我期待着成功的合作伙伴关系，并向全球客户提供我们的专有技术。”，Vipergen首席执行官Nils Jakob Vest Hansen博士说。。

About Aurigene:

关于Aurigene：

Aurigene, a Dr. Reddy’s Laboratories company, is a global contract research, development, and manufacturing organization (CRDMO built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development, and manufacturing of small and large molecules. We offer integrated and standalone services for discovery chemistry, biotherapeutics discovery, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing..

Aurigene是Reddy博士的实验室公司，是一家全球合同研究、开发和制造组织（CRDMO），建立在加速创新的传统基础上，并以在药物发现、开发和制造小分子和大分子方面的丰富经验为后盾。我们为发现化学、生物治疗发现、发现生物学、临床I-III期计划的开发和制造服务、监管提交批次和商业制造提供集成和独立服务。。

About Vipergen:

关于Vipergen：

Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan.

Vipergen是基于DNA编码文库（DEL）技术的小分子药物发现服务的世界领先供应商，也是第一家也是唯一一家能够在活细胞内筛选DEL的公司。Vipergen通过与领先的制药和生物技术公司（包括美国、欧盟和日本的顶尖制药公司）建立资金发现合作伙伴关系，提供其专有的一套领先的DEL技术。